Message #9 From:
NewsBot Date: December 12, 2005 03:03:00 AM
ADXS News Two Leading Biotech Publications Report on Advaxis' Potential Treatment for Cervical Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--Dec. 12, 2005--Two leading biotech publications reported that Advaxis, Inc. (ADXS.OB) successfully demonstrated in testing of mice at the University of Pennslyvania that a live listeria vaccine can eradicate existing, rapidly-growing breast tissue tumors.
Genetic Engineering News, in its December 8th issue, reported that Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania, and chair person of Advaxis' Scientific Advisory Board, presented a study in a recent issue of the Journal of Immunology that ten years of scientific research produced evidence of the cancer-fighting properties of a live modified listeria cancer vaccine she created.
Dr. Paterson's research indicates that listeria activates the body's cytotoxic T cells to help the immune system take a stronger stance in the presence of cancer cells, Genetic Engineering News reported.
"If Lovaxin C is successful in clinical trials it has the potential for treating cervical cancer in early and late stage disease, including those women who have positive pap smears and currently require surgery," explained John Rothman, Advaxis'vice president of clinical development.
DrugResearcher.com, reported in its December 6th issue that Advaxis' Lovaxin C, a proprietary listeria vaccine, "could soon be on the horizon after researchers took a giant step in development of effective cancer-fighting vaccines that appear to be able to stop and reverse cancer growth."
"The newly developed vaccine therapies for cervical cancer are directed at those women who have not been exposed to HPV, the viral cause of cervical cancer," DrugResearcher.com reported. "Lovaxin C, which will be entering a Phase I/II clinical trial, is intended to cure women who already have cervical cancer as a result of HPV exposure."
Based in Princeton, New Jersey. Advaxis is developing proprietary Listeria cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania, and chair person of Advaxis' Scientific Advisory Board.. Advaxis' is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Listeria monocytogenes based system, which utilizes two immunological mechanisms (Innate and Classical Immunity) to develop safer and more effective Listeria based cancer vaccines. Advaxis is the exclusive licensee of a patented broadly enabling Listeria platform technology that can elicit effective anti-tumor responses. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets cervical and head and neck cancers. Further Listeria vaccines in development target breast, ovarian and lung cancers. Advaxis is entering a Phase I/II clinical trial in late 2005. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
